Targeted Therapies in Cancer: To Be or Not to Be, Selective

Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Skye Montoya, Deborah Soong, Nina Nguyen, Maurizio Affer, Sailasya P. Munamarty, Justin Taylor
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cancer targeted therapies resistance mechanisms receptor tyrosine kinases single kinase inhibitors multikinase inhibitors Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/cfeba3ffd4da484b9306a09a2d8a6e44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfeba3ffd4da484b9306a09a2d8a6e44
record_format	dspace
spelling	oai:doaj.org-article:cfeba3ffd4da484b9306a09a2d8a6e442021-11-25T16:49:24ZTargeted Therapies in Cancer: To Be or Not to Be, Selective10.3390/biomedicines91115912227-9059https://doaj.org/article/cfeba3ffd4da484b9306a09a2d8a6e442021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1591https://doaj.org/toc/2227-9059Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefore the pathways they activate, cancers can be slowed or completely eradicated, leading to partial or complete remissions for many cancer types. Unfortunately, for many patients, resistance to targeted therapies, such as kinase inhibitors, ultimately develops and can necessitate multiple lines of treatment. Drug resistance can either be de novo or acquired after months or years of drug exposure. Since resistance can be due to several unique mechanisms, there is no one-size-fits-all solution to this problem. However, combinations that target complimentary pathways or potential escape mechanisms appear to be more effective than sequential therapy. Combinations of single kinase inhibitors or alternately multikinase inhibitor drugs could be used to achieve this goal. Understanding how to efficiently target cancer cells and overcome resistance to prior lines of therapy became imperative to the success of cancer treatment. Due to the complexity of cancer, effective treatment options in the future will likely require mixing and matching these approaches in different cancer types and different disease stages.Skye MontoyaDeborah SoongNina NguyenMaurizio AfferSailasya P. MunamartyJustin TaylorMDPI AGarticlecancertargeted therapiesresistance mechanismsreceptor tyrosine kinasessingle kinase inhibitorsmultikinase inhibitorsBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1591, p 1591 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer targeted therapies resistance mechanisms receptor tyrosine kinases single kinase inhibitors multikinase inhibitors Biology (General) QH301-705.5
spellingShingle	cancer targeted therapies resistance mechanisms receptor tyrosine kinases single kinase inhibitors multikinase inhibitors Biology (General) QH301-705.5 Skye Montoya Deborah Soong Nina Nguyen Maurizio Affer Sailasya P. Munamarty Justin Taylor Targeted Therapies in Cancer: To Be or Not to Be, Selective
description	Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefore the pathways they activate, cancers can be slowed or completely eradicated, leading to partial or complete remissions for many cancer types. Unfortunately, for many patients, resistance to targeted therapies, such as kinase inhibitors, ultimately develops and can necessitate multiple lines of treatment. Drug resistance can either be de novo or acquired after months or years of drug exposure. Since resistance can be due to several unique mechanisms, there is no one-size-fits-all solution to this problem. However, combinations that target complimentary pathways or potential escape mechanisms appear to be more effective than sequential therapy. Combinations of single kinase inhibitors or alternately multikinase inhibitor drugs could be used to achieve this goal. Understanding how to efficiently target cancer cells and overcome resistance to prior lines of therapy became imperative to the success of cancer treatment. Due to the complexity of cancer, effective treatment options in the future will likely require mixing and matching these approaches in different cancer types and different disease stages.
format	article
author	Skye Montoya Deborah Soong Nina Nguyen Maurizio Affer Sailasya P. Munamarty Justin Taylor
author_facet	Skye Montoya Deborah Soong Nina Nguyen Maurizio Affer Sailasya P. Munamarty Justin Taylor
author_sort	Skye Montoya
title	Targeted Therapies in Cancer: To Be or Not to Be, Selective
title_short	Targeted Therapies in Cancer: To Be or Not to Be, Selective
title_full	Targeted Therapies in Cancer: To Be or Not to Be, Selective
title_fullStr	Targeted Therapies in Cancer: To Be or Not to Be, Selective
title_full_unstemmed	Targeted Therapies in Cancer: To Be or Not to Be, Selective
title_sort	targeted therapies in cancer: to be or not to be, selective
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cfeba3ffd4da484b9306a09a2d8a6e44
work_keys_str_mv	AT skyemontoya targetedtherapiesincancertobeornottobeselective AT deborahsoong targetedtherapiesincancertobeornottobeselective AT ninanguyen targetedtherapiesincancertobeornottobeselective AT maurizioaffer targetedtherapiesincancertobeornottobeselective AT sailasyapmunamarty targetedtherapiesincancertobeornottobeselective AT justintaylor targetedtherapiesincancertobeornottobeselective
_version_	1718412924978987008

Targeted Therapies in Cancer: To Be or Not to Be, Selective

Ejemplares similares